
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics demonstrated strong sales growth in its nanochannel array flowcells, with a notable 17% increase from 6,165 units sold in 2Q24 to 7,233 units in 2Q25, and a 7% increase from 7,835 units in 3Q24 to 8,390 units in 3Q25. The company's revenue from consumables and software also improved, rising by 16% year-over-year in 2Q25, leading to an overall 11% increase in combined revenue after adjusting for discontinued services. Additionally, Bionano's installation expectations for the OGM system are projected to rise to 20-25 units for FY2025, up from 15-20, indicating positive momentum in both existing and new markets, notably in Japan.
Bears say
Bionano Genomics faces significant risks that contribute to a negative outlook for its stock, including lower than projected market uptake of its products and reduced utilization of existing systems. Additionally, the company's ability to secure further capital for operations is uncertain, which raises concerns regarding its financial stability and potential dilution risks for shareholders. These factors, combined with a conservative EV/Revenue multiple of 1.2x, suggest that the company may struggle to achieve its projected sales and maintain its current valuation metrics.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares